Skip to main content
Erschienen in: European Radiology 1/2016

01.01.2016 | Chest

CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer

verfasst von: Stefania Rizzo, Francesco Petrella, Valentina Buscarino, Federica De Maria, Sara Raimondi, Massimo Barberis, Caterina Fumagalli, Gianluca Spitaleri, Cristiano Rampinelli, Filippo De Marinis, Lorenzo Spaggiari, Massimo Bellomi

Erschienen in: European Radiology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To assess the association between CT features and EGFR, ALK, KRAS mutations in non-small cell lung cancer.

Methods

Patients undergoing chest CT and testing for the above gene mutations were included. Qualitative evaluation of CTs included: lobe; lesion diameter; shape; margins; ground-glass opacity; density; cavitation; air bronchogram; pleural thickening; intratumoral necrosis; nodules in tumour lobe; nodules in non-tumour lobes; pleural retraction; location; calcifications; emphysema; fibrosis; pleural contact; pleural effusion. Statistical analysis was performed to assess association of features with each gene mutation. ROC curves for gene mutations were drawn; the corresponding area under the curve was calculated. P-values <0.05 were considered significant.

Results

Of 285 patients, 60/280 (21.43 %) were positive for EGFR mutation; 31/270 (11.48 %) for ALK rearrangement; 64/240 (26.67 %) for KRAS mutation. EGFR mutation was associated with air bronchogram, pleural retraction, females, non-smokers, small lesion size, and absence of fibrosis. ALK rearrangements were associated with age and pleural effusion. KRAS mutation was associated with round shape, nodules in non-tumour lobes, and smoking.

Conclusions

This study disclosed associations between CT features and alterations of EGFR (air bronchogram, pleural retraction, small lesion size, absence of fibrosis), ALK (pleural effusion) and KRAS (round lesion shape, nodules in non-tumour lobes).

Key Points

Air bronchogram, pleural retraction, small size relate to EGFR mutation in NSCLC.
Pleural effusion and younger age relate to ALK mutation.
Round lesion shape, nodules in non-tumour lobes relate to KRAS mutation.
Literatur
1.
Zurück zum Zitat Buettner R, Wolf J, Thomas RK (2013) Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 31(15):1858–1865CrossRefPubMed Buettner R, Wolf J, Thomas RK (2013) Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 31(15):1858–1865CrossRefPubMed
2.
Zurück zum Zitat Jorge SE, Kobayashi SS, Costa DB (2014) Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 47(11):929–933PubMedCentralCrossRefPubMed Jorge SE, Kobayashi SS, Costa DB (2014) Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 47(11):929–933PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Seto T, Kiura K, Nishio M et al (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol 14:590–598CrossRefPubMed Seto T, Kiura K, Nishio M et al (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol 14:590–598CrossRefPubMed
6.
Zurück zum Zitat Rodenhuis S, Slebos RJ (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665–2669s Rodenhuis S, Slebos RJ (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665–2669s
7.
Zurück zum Zitat Gerber DE, Gandhi L, Costa DB (2014) Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book 34:e353–e365CrossRef Gerber DE, Gandhi L, Costa DB (2014) Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book 34:e353–e365CrossRef
8.
Zurück zum Zitat Colen R, Foster I, Gatenby R et al (2014) NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures. Transl Oncol 24(7(5)):556–569CrossRef Colen R, Foster I, Gatenby R et al (2014) NCI Workshop Report: Clinical and Computational Requirements for Correlating Imaging Phenotypes with Genomics Signatures. Transl Oncol 24(7(5)):556–569CrossRef
9.
Zurück zum Zitat Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892CrossRefPubMed Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892CrossRefPubMed
10.
Zurück zum Zitat Kuo MD, Jamshidi N (2014) Behind the numbers: Decoding molecular phenotypes with radiogenomics–guiding principles and technical considerations. Radiology 270(2):320–325CrossRefPubMed Kuo MD, Jamshidi N (2014) Behind the numbers: Decoding molecular phenotypes with radiogenomics–guiding principles and technical considerations. Radiology 270(2):320–325CrossRefPubMed
11.
Zurück zum Zitat Rutman AM, Kuo MD (2009) Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 70(2):232–241CrossRefPubMed Rutman AM, Kuo MD (2009) Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 70(2):232–241CrossRefPubMed
12.
Zurück zum Zitat Hsu JS, Huang MS, Chen CY et al (2014) Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging 29:357–363CrossRefPubMed Hsu JS, Huang MS, Chen CY et al (2014) Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging 29:357–363CrossRefPubMed
13.
Zurück zum Zitat Gevaert O, Xu J, Hoang CD et al (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data–methods and preliminary results. Radiology 264(2):387–396PubMedCentralCrossRefPubMed Gevaert O, Xu J, Hoang CD et al (2012) Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data–methods and preliminary results. Radiology 264(2):387–396PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272(2):568–576CrossRefPubMed Yamamoto S, Korn RL, Oklu R et al (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 272(2):568–576CrossRefPubMed
15.
Zurück zum Zitat Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds) (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARCPress, Lyon Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds) (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARCPress, Lyon
16.
17.
Zurück zum Zitat Jain R, Poisson L, Gutman D et al (2014) Outcome prediction in patients with glioblastoma using imaging, clinical and genomic biomarkers: focus on the non-enhancing component of the tumor. Radiology 272(2):484–493PubMedCentralCrossRefPubMed Jain R, Poisson L, Gutman D et al (2014) Outcome prediction in patients with glioblastoma using imaging, clinical and genomic biomarkers: focus on the non-enhancing component of the tumor. Radiology 272(2):484–493PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Karlo CA, Di Paolo PL, Chaim J et al (2013) Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. Radiology 270(2):464–471PubMedCentralCrossRefPubMed Karlo CA, Di Paolo PL, Chaim J et al (2013) Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. Radiology 270(2):464–471PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Cooke SL, Ng CK, Melnyk N et al (2010) Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29(35):4905–4913PubMedCentralCrossRefPubMed Cooke SL, Ng CK, Melnyk N et al (2010) Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29(35):4905–4913PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMed Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMed
22.
Zurück zum Zitat Dacic S (2013) Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol 66(10):870–874CrossRefPubMed Dacic S (2013) Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol 66(10):870–874CrossRefPubMed
23.
Zurück zum Zitat Dacic S, Shuai Y, Yousem S et al (2010) Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23:159–168CrossRefPubMed Dacic S, Shuai Y, Yousem S et al (2010) Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23:159–168CrossRefPubMed
24.
Zurück zum Zitat Chang YL, Lin MW, Shih JY, Wu CT, Lee YC (2012) The significance of visceral pleural surface invasion in 321 cases of non-small cell lung cancers with pleural retraction. Ann Surg Oncol 19(9):3057–3064CrossRefPubMed Chang YL, Lin MW, Shih JY, Wu CT, Lee YC (2012) The significance of visceral pleural surface invasion in 321 cases of non-small cell lung cancers with pleural retraction. Ann Surg Oncol 19(9):3057–3064CrossRefPubMed
25.
Zurück zum Zitat Yoshino I, Nakanishi R, Kodate M et al (2000) Pleural retraction and intra-tumoral air-bronchogram as prognostic factors for stage I pulmonary adenocarcinoma following complete resection. Int Surg 85(2):105–112PubMed Yoshino I, Nakanishi R, Kodate M et al (2000) Pleural retraction and intra-tumoral air-bronchogram as prognostic factors for stage I pulmonary adenocarcinoma following complete resection. Int Surg 85(2):105–112PubMed
26.
Zurück zum Zitat Toh CK, Gao F, Lim WT et al (2006) Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24(15):2245–2251CrossRefPubMed Toh CK, Gao F, Lim WT et al (2006) Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24(15):2245–2251CrossRefPubMed
27.
Zurück zum Zitat Nakada T, Okumura S, Kuroda H, et al (2014) Imaging Characteristics in ALK Fusion-Positive Lung Adenocarcinomas by Using HRCT. Ann Thorac Cardiovasc Surg. Jun 3. [Epub ahead of print] Nakada T, Okumura S, Kuroda H, et al (2014) Imaging Characteristics in ALK Fusion-Positive Lung Adenocarcinomas by Using HRCT. Ann Thorac Cardiovasc Surg. Jun 3. [Epub ahead of print]
28.
Zurück zum Zitat Martin P, Leighl NB, Tsao MS, Shepherd FA (2013) KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 8(5):530–542PubMed Martin P, Leighl NB, Tsao MS, Shepherd FA (2013) KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 8(5):530–542PubMed
29.
Zurück zum Zitat Slebos RJ, Kibbelaar RE, Dalesio O et al (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565CrossRefPubMed Slebos RJ, Kibbelaar RE, Dalesio O et al (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565CrossRefPubMed
30.
Zurück zum Zitat Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFRtargeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972CrossRefPubMed Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFRtargeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972CrossRefPubMed
31.
Zurück zum Zitat Mao C, Qiu LX, Liao RY et al (2010) KRAS mutations and resistance to EGFRTKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69:272–278CrossRefPubMed Mao C, Qiu LX, Liao RY et al (2010) KRAS mutations and resistance to EGFRTKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69:272–278CrossRefPubMed
32.
Zurück zum Zitat Ruppert AM, Lerolle U, Carette MF et al (2011) Coexisting pulmonary nodules in operable lung cancer: prevalence and probability of malignancy. Lung Cancer 74(2):233–238CrossRefPubMed Ruppert AM, Lerolle U, Carette MF et al (2011) Coexisting pulmonary nodules in operable lung cancer: prevalence and probability of malignancy. Lung Cancer 74(2):233–238CrossRefPubMed
33.
Zurück zum Zitat Riely GJ, Kris MG, Rosenbaum D et al (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14:5731–5734PubMedCentralCrossRefPubMed Riely GJ, Kris MG, Rosenbaum D et al (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14:5731–5734PubMedCentralCrossRefPubMed
34.
Zurück zum Zitat Ou SH (2013) Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? J Clin Pathol 66(10):839–846CrossRefPubMed Ou SH (2013) Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? J Clin Pathol 66(10):839–846CrossRefPubMed
35.
Zurück zum Zitat Lee HJ, Kim YT, Kang CH et al (2013) Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 268(1):254–264CrossRefPubMed Lee HJ, Kim YT, Kang CH et al (2013) Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 268(1):254–264CrossRefPubMed
Metadaten
Titel
CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer
verfasst von
Stefania Rizzo
Francesco Petrella
Valentina Buscarino
Federica De Maria
Sara Raimondi
Massimo Barberis
Caterina Fumagalli
Gianluca Spitaleri
Cristiano Rampinelli
Filippo De Marinis
Lorenzo Spaggiari
Massimo Bellomi
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 1/2016
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-3814-0

Weitere Artikel der Ausgabe 1/2016

European Radiology 1/2016 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.